Previsioni

Il prezzo obiettivo medio degli analisti è 19,80 € (+123,98%). La mediana è 19,80 € (+123,98%).

Acquista	3
Mantieni	0
Vendi	0

Notizie Vai al feed delle notizie

Daxor completes registered capital raise of about $8.1 million

Daxor sold 765,958 common shares in a registered direct placement at $11.75 each and generated net proceeds of approximately $8.14 million after fees. The placement was made under a shelf registration the SEC declared effective on January 20, 2026; Lake Street Capital Markets acted as placement agent. The stock is currently trading slightly above the issue price at $12.28; market capitalization is around $61.21 million. » Altro su de.investing.com
Daxor jumps 40% after FDA approval for new blood volume analysis device

Shares of Daxor Corporation surged 40% after the company received 510(k) clearance from the US Food and Drug Administration (FDA) for its new blood volume analysis device. The compact handheld device provides faster and more accurate results for fluid management in various medical conditions and was developed on behalf of the US Department of Defense. Studies show significant clinical benefits and cost savings from using Daxor's technology. » Altro su de.investing.com
Daxor confirms board and auditor, presents progress on blood volume analyzers

At its annual general meeting, Daxor elected six board members and confirmed Bush & Associates, CPA, as its auditor. The company submitted its new blood volume analyzer to the FDA and presented research demonstrating the superiority of its technology in treating heart failure. Daxor continues to collaborate with the US Department of Defense and the NIH on innovative healthcare solutions. » Altro su de.investing.com

Dividendi storici Dividendi

Tutte le metriche sui dividendi Tutte le metriche

Nel 2025, DAXOR CORP. DL -,01 ha già distribuito 0,0378 € di dividendi. L'ultimo pagamento è avvenuto a luglio 2025.

Dati finanziari dell'azienda

Nell'ultimo trimestre, DAXOR CORP. DL -,01 ha registrato ricavi pari a 20,17K € e un utile netto di -2,9 Mln €

(EUR)	giugno 2026	YoY
Ricavi	20,17K	-
Utile lordo	-52,86K	-
Utile netto	-2,9 Mln	-
EBITDA	-2,9 Mln	-

Dati fondamentali

Metrica	Valore
Capitalizzazione di mercato	51,63 Mln €
Numero di azioni	5,84 Mln
Massimo/minimo a 52 settimane	12,71 € - 7,37 €
Dividendi	No
Beta	0,27
Rapporto P/E	8,35
Rapporto PEG	0,04
Rapporto P/B	0,99
Rapporto P/S	387,16

Profilo aziendale

Die Daxor Corporation, ein Medizintechnikunternehmen, bietet Technologien zur Messung des Blutvolumens an, die sich auf Blutvolumentests konzentrieren. Das Unternehmen entwickelt und vermarktet den BVA-100 Blood Volume Analyzer, einen diagnostischen Bluttest, der eine sichere, genaue und objektive Quantifizierung des Blutvolumenstatus und der Zusammensetzung im Vergleich zu patientenspezifischen Normen ermöglicht und bei einer Vielzahl von medizinischen und chirurgischen Erkrankungen eingesetzt wird. Das Unternehmen war früher unter dem Namen Idant Corporation bekannt und änderte im Mai 1973 seinen Namen in Daxor Corporation. Die Daxor Corporation wurde 1971 gegründet und hat ihren Hauptsitz in Oak Ridge, Tennessee.